Experienced advisor on Medicare and Medicaid programs

Elizabeth Gebarski advises clients on health care regulatory and compliance issues, business development, government program enrollment issues and licensing issues. Her experience includes:

• Health care transactions
• Medicare and Medicaid program compliance from the provider and plan perspective, including Medicare and Medicaid notification and filing requirements
• Pharmaceutical industry matters, including Federal and State permit and licensure issues and DEA Requirements for controlled substance distribution and prescription dispensing

Elizabeth takes a holistic approach, providing legal strategy within the client’s broader business context. She highlights the implications a decision will have on their business and, instead of simply answering the question asked, she understands the "why" and suggests alternatives that will resolve the underlying issue.

Bar Admissions

• Wisconsin

Education

• Marquette University Law School (J.D., cum laude, 2013)
  • Marquette Elder's Advisor, Editor-in-Chief
  • Dean's List, Four Semesters
  • CALI Award (highest grade), Managed Healthcare

• University of Michigan (B.A., 2010)
  • James B. Angell Scholar, 2010

• "Approved – Cybersecurity Act of 2015"
• "Breaking Down the Proposed Omnibus Guidance – Child Sites"
• "Breaking Down the Proposed Omnibus Guidance – Covered Entity Eligibility, Registration & Termination"
• "Comparing 340B University and the 340B Coalition Conference"
• "Cyber Health Crisis: How to Manage the Risk"
• "Don't Forget Child Sites Under The 340B Omnibus Guidance"
• "Don’t Expose Your ePHI by Using Vulnerable Third-Party Applications"
• "End of Year Thoughts on FTC Data & Security Requirements"
• "Federal Agencies Release Guidance on Cyber Sharing"
• "Finally! HRSA Proposes Manufacturer Civil Monetary Penalties"
• "Health Law"
• "Health Law"
• "How Much Will You Pay for an Inaccurate 340B Ceiling Price?"
• "Key Dates Approaching for Title X Family Planning Grantees in the 340B Program"
• "Key Takeaway from 340B Conferences – Audits"
• "Near Miss on Congressional Overhaul of 340B Program"
• "PhRMA 2-0 in The Orphan Drug Wars"
• "Site Neutral Payments Put 340B Child Sites in Jeopardy"
• "Target Settles with Visa Card Issuers for Up to $67 Million"
• "The 340B Drug Pricing Program Omnibus Guidance – in Two Parts"
• "The 340B Drug Pricing Program Omnibus Guidance – Part Two"
• "The End of the PHE: Considerations for Medicare & Medicaid Providers and Suppliers"
• "The Omnibus Guidance is Dead!"
• "The Proposed 340B Drug Pricing Program Omnibus Guidelines Have Landed
• "The Year in Review - A Legal Case Update"
• "Top Takeaway from 340B University and 340B Coalition Conference"
• "Trends in State Licensing and Medicare & Medicaid Enrollment"
• "U.S. Senate Encourages Sharing – of Cyber Threat Indicators, That Is"
• "Unexpected Uncertainty For The 340B Drug Pricing Program"
• Are You Interested in the FDA's Guidance on Outsourcing Facilities? Your Time to Comment Is Ending Soon!
• Doing a Health Care Transaction in Illinois? Be Prepared to Tell the Attorney General
• New Year, New CMS Pharmacy/DMEPOS Regulations on Refill, Deactivation, Revocation & Revalidation
• OIG Blesses Arrangement Involving "Far Removed" Excluded Person
• T​he 340B Program Mega Guidance: Muddying the Water for All Stakeholders
• Wait, What? Palmetto GBA and Novitas Solutions Now Administer Medicare DMEPOS
• What Your Medicaid Pharmacy Administrator is Working On
• “The 340B Drug Pricing Program: Staying Afloat in the Wake of the Omnibus Guidance”

Seminar

• 2022 Pharmacy Law Symposium
• 2023 Pharmacy Law Symposium
• Pharmacy Law Update